Figure 1 Environmental factors contributing to IBD pathogenesis

Slides:



Advertisements
Similar presentations
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Advertisements

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Nephrol. doi: /nrneph
Figure 4 Activation of clopidogrel via cytochrome P450
Figure 2 Proinflammatory mechanisms in CKD
Figure 1 Factors underlying metabolic alterations in osteoarthritis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 7 Treatment algorithm for perianal fistulizing disease
Figure 6 Injection of mesenchymal stem cells in perianal fistulas
Figure 2 A stage-based approach to the treatment of NAFLD
Figure 1 Gut microorganisms at the intersection of several diseases
Figure 5 Lipid droplet consumption
Figure 4 Simple perianal fistula
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 The microbiome–gut–brain axis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 The T-cell cytokine tree in IBD
Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Figure 1 Metabolic profiling as a tool for studying rheumatic diseases
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 4 Giant lipid droplet formation
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.
Figure 6 Combination therapy for HCC
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.
Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.
Figure 1 Definition and concept of ACLF
Figure 2 Switching of biologic agents and biosimilars
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Cardiol. doi: /nrcardio
Figure 7 Example colonic high-resolution manometry
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.
Figure 1 Median coverage and distribution by
in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)
Figure 5 Chrononutrition in the liver
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Possible therapeutic targets to decrease hepatic steatosis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.
Nat. Rev. Urol. doi: /nrurol
Figure 1 The current model of the pathogenesis of SLE
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 5 Systems biological model of IBS
Figure 5 PPIs and adverse events with proven and unproven causality
Eligibility criteria for inclusion as an expert Delphi panellist
Figure 4 Local species pools that contribute to the
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Lifelong influences on the gut microbiome from
Figure 1 NAFLD pathogenesis
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Classifications and appearance of CCAs
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Presentation transcript:

Figure 1 Environmental factors contributing to IBD pathogenesis Figure 1 | Environmental factors contributing to IBD pathogenesis. Environmental factors including conception, maternal influences on the fetus, mode of birth, early childhood and diet and lifestyle exposures during adulthood modify the risk of development of Crohn's disease and ulcerative colitis. Ananthakrishnan, A. N. et al. (2017) Environmental triggers in IBD: a review of progress and evidence Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.136